title: Degradation of bidentate-coordinated platinum(II)-based DNA intercalators by reduced L-glutathione.
abstract: We have examined the interaction of [(5,6-dimethyl-1,10-phenanthroline)(1S,2S-diaminocyclohexane)platinum(II)] (2+) (1, 56MESS), [(5-methyl-1,10-phenanthroline)(1S,2S-diaminocyclohexane)platinum(II)] (2+) (2, 5MESS), [(5,6-dimethyl-1,10-phenanthroline)(1R,2R-diaminocyclohexane)platinum(II)] (2+) (3, 56MERR), and [(5,6-dimethyl-1,10-phenanthroline)(ethylenediamine)platinum(II)] (2+) (4, 56MEEN) with reduced L-glutathione and L-methionine. Both thiols degrade all four complexes, mainly by displacing the ancillary ligand and forming a doubly bridged dinuclear complex. The degradation half-life of all the complexes with methionine is >7 days, indicating that these reactions are not biologically relevant. The rate of degradation by glutathione appears to be particularly important and shows an inverse correlation to cytotoxicity. The least active complex, 4 (t 1/2 glutathione: 20 h), degrades fastest, followed by 3 (31 h), 2 (40 h), and 1 (68 h). The major degradation product, [bis-mu-{reduced L-glutathione}bis{5,6-dimethyl-1,10-phenanthroline}bis{platinum(II)}] (2+) (5, 56MEGL), displays no cytotoxicity and is excluded as the source of the anticancer activity. Once bound by glutathione, these metal complexes do not then form coordinate bonds with guanosine. Partial encapsulation of the complexes within cucurbit[n]urils is able to stop the degradation process.
authors.affiliation: School of Biomedical and Health Sciences, University of Western Sydney, Locked Bag 1797, Penrith South DC, 1797, NSW, Australia.
authors.forename: Sharon
authors.initials: S
authors.lastname: Kemp
authors.forename: Nial J
authors.initials: NJ
authors.lastname: Wheate
authors.forename: Michelle J
authors.initials: MJ
authors.lastname: Pisani
authors.forename: Janice R
authors.initials: JR
authors.lastname: Aldrich-Wright
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology; D001952:Bridged-Ring Compounds / Q000737:chemistry; D049109:Cell Proliferation / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D005978:Glutathione / Q000737:chemistry*; D006157:Guanosine Monophosphate / Q000737:chemistry; D007093:Imidazoles / Q000737:chemistry; D007364:Intercalating Agents / Q000737:chemistry* / Q000494:pharmacology; D007939:Leukemia L1210; D008024:Ligands; D009682:Magnetic Resonance Spectroscopy; D008715:Methionine / Q000737:chemistry; D051379:Mice; D009944:Organoplatinum Compounds / Q000737:chemistry* / Q000494:pharmacology; D021241:Spectrometry, Mass, Electrospray Ionization; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured; D047028:Macrocyclic Compounds; D000099246:Cucurbit(n)urils
chemical_list: D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D005978:Glutathione; D006157:Guanosine Monophosphate; D007093:Imidazoles; D007364:Intercalating Agents; D008024:Ligands; D008715:Methionine; D009944:Organoplatinum Compounds; C529817:(5,6-dimethyl-1,10-phenanthroline)(1,2-diaminocyclohexane)platinum(II); C529819:(5,6-dimethyl-1,10-phenanthroline)(ethylenediamine)platinum(II); C529818:(5-methyl-1,10-phenanthroline)(1,2-diaminocyclohexane)platinum(II); C456276:cucurbit(7)uril; D047028:Macrocyclic Compounds; D000099246:Cucurbit(n)urils; C507198:cucurbit(8)uril; C454805:cucurbit(6)uril